All In Biotech

Drug Trial Radar · NCT07557121

Safety and Efficacy of AIV007 Periocular Injection in Patients With Neovascular Age-Related Macular Degeneration

A Phase 2, Multicenter, Randomized, Active-controlled Trial of the Safety and Efficacy of AIV007 by Periocular Injection in Patients With Neovascular Age-Related Macular Degeneration

Last checked: Nov 19, 2026Latest source record: Nov 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

35

Planned (sponsor's estimate)

Start

Jul 1, 2026

Primary completion

Jun 30, 2027

Study completion Aug 23, 2027

Sponsor

Lead sponsor
AiViva BioPharma, Inc.Industry
Sponsor type
Industry
Collaborators
ClinDatrix, Inc.
First posted
Apr 29, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 50 years, up to 85 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this study is to evaluate whether AIV007 provides benefits to patients with neovascular age-related macular degeneration in improving vision and that it has an acceptable safety profile. Participants will receive either a periocular injection of AIV007 or intravitreal injection of Eylea (control arm) to the study eye and return to the clinic monthly for safety and efficacy observations and/or continued treatment. Participants may receive additional treatment(s) if they meet specified criteria.

Conditions

  • Neovascular (Wet) Age-Related Macular Degeneration

Interventions

  • AIV007Drug

    6 mg or 8 mg dose

  • EYLEA® (aflibercept) Injection 2 mg (0.05mL)Biological

    Eylea 2 mg, marketed product

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Best-corrected Visual AcuityTime frame: Month 6

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Macula and Vitreous Center

    Torrance, California · Recruiting

  • Valley Retina Institute, P.A.

    McAllen, Texas · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.